For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6351-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13531-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6404-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

Name:	us-gaap_ConcentrationRiskPercentage1
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

SEGMENT INFORMATION (Detail Narrative)	3 Months Ended		9 Months Ended
SEGMENT INFORMATION (Detail Narrative)	Sep. 30, 2015 USD ($)	Sep. 30, 2014 USD ($)	Sep. 30, 2015 USD ($) Number	Sep. 30, 2014 USD ($)
Number of reportable segments \| Number			2
Sales revenue	$ 34,131	$ 89,600	$ 223,621	$ 135,774
UNITED STATES
Sales revenue			10,200
Viralprotec Segment [Member]
Sales revenue	9,760		$ 91,969
Viralprotec Segment [Member] \| Sales Revenue, Net [Member]
Concentration risk, percentage			11.00%
Nanotechnology Segment [Member]
Sales revenue	$ 24,371	$ 89,600	$ 131,652	$ 135,774
Nanotechnology Segment [Member] \| Sales Revenue, Net [Member]
Concentration risk, percentage			64.00%	93.00%